Apoptosis
Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
- Caspase(102)
- 14.3.3 Proteins(2)
- Apoptosis Inducers(45)
- Bax(7)
- Bcl-2 Family(122)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(67)
- MDM2(15)
- p53(128)
- PC-PLC(5)
- PKD(8)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(151)
- Other Apoptosis(900)
- Apoptosis Detection
- Caspase Substrate
- APC(6)
- PD-1/PD-L1 interaction(91)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(32)
Apoptosis 相关产品(2721)
- GC68857CetrelimabCAS: 2050478-92-5
Cetrelimab (JNJ 63723283; JNJ 3283) 是一种靶向 PD-1 的人源化 IgG4κ 单克隆抗体。Cetrelimab 结合 PD-1 的 Kd 为 1.72 nM (HEK293 细胞)。由此,Cetrelimab 阻断 PD-1 与 PD-L1 和 PD-L2 的相互作用 (IC50 分别为 111.7 ng/mL 和 138.6 ng/mL)。Cetrelimab 还刺激外周 T 细胞,增加细胞因子 (IFN-γ, IL-2, TNF-α) 水平,并抑制体内肿瘤生长。
- GC68873Citric acid trisodiumCAS: 68-04-2纯度: >98.00%
Citric acid trisodium 是一种天然防腐剂和食品酸味增强剂。Citric acid trisodium 诱导细胞凋亡 (apoptosis) 和细胞周期停滞在 G2/M 期和 S 期。Citric acid trisodium 通过降低抗氧化酶活性引起肝脏的氧化损伤。Citric acid trisodium 对小鼠造成肾毒性。
- GC68882Cleomiscosin ACAS: 76948-72-6
Cleomiscosin A 是产于 Macaranga adenantha 的香豆素类木质素。Cleomiscosin A 对小鼠腹腔巨噬细胞分泌 TNF-alpha 具有活性。
- GC68903cRIPGBM chlorideCAS: 2361988-77-2纯度: >99.00%
cRIPGBM chloride 是一种口服有效的促凋亡衍生物,cRIPGBM 可从多形性胶质母细胞瘤 (GBM) 癌症干细胞 (CSC) 中产生。cRIPGBM chloride 靶向受体相互作用蛋白激酶 2 (RIPK2) 以诱导半胱天冬酶 caspase 1 依赖性细胞凋亡。cRIPGBM chloride 抑制 RIPK2/TAK1 (促存活复合物) 的形成,并增加 RIPK2/caspase 1 (促凋亡复合物) 的形成。cRIPGBM chloride 在动物模型中发挥了强力的体内抗肿瘤活性。
- GC68956Dehydrocorydaline (hydroxyl)纯度: >99.00%
Dehydrocorydaline hydroxyl (13-Methylpalmatine) 是一种生物碱。Dehydrocorydaline hydroxyl 调节 Bax,Bcl-2 蛋白表达;激活 caspase-7,caspase-8,并使 PARP 失活。Dehydrocorydaline hydroxyl 能增强 p38 MAPK 活化,具有抗炎、抗癌等功效。Dehydrocorydaline hydroxyl 具有强大的抗疟疾作用,并具低细胞毒性 (细胞生存力> 90%), P. falciparum 3D7 strain (IC50=38 nM)。
- GC69001DostarlimabCAS: 2022215-59-2纯度: >95.00%
Dostarlimab (TSR-042) 是一种人源化抗 PD-1 单克隆抗体。Dostarlimab 与人 PD-1 具有高亲和力,并竞争性地抑制其与其配体 PD-L1 和 PD-L2 的相互作用,IC50s 分别为 1.8 nM 和 1.5 nM。
- GC69009(D)-PPA 1 TFA纯度: >99.00%
(D)-PPA 1 TFA 是一种抗水解 D 肽拮抗剂。(D)-PPA 1 TFA 是一种有效的 PD-1/PD-L1 抑制剂。(D)-PPA 1 TFA 与 PD-1 结合的亲和力为 0.51 μM,体内外均有效。
- GC69062EnavatuzumabCAS: 1062149-33-0纯度: >95.00%
Enavatuzumab (PDL192; ABT-361) 是一种人源化 IgG1 单克隆抗体,靶向 TNF 样细胞凋亡弱诱导剂受体 (TWEAK)。TWEAK (Fn14; TNFRSF12A) 是 TWEAK 受体 (TweakR) 的天然配体,可刺激多种细胞反应。Enavatuzumab 通过直接的 TweakR 信号和抗体依赖性细胞介导的细胞毒性 (ADCC) 诱导肿瘤生长抑制。Enavatuzumab 可以主动募集和激活骨髓效应细胞来杀死肿瘤细胞。Enavatuzumab 在体外和体内抑制各种人类 TweakR 阳性癌细胞系和异种移植物的生长。
- GC69070Enpp/Carbonic anhydrase-IN-1CAS: 2883495-35-8纯度: >99.00%
Enpp/Carbonic anhydrase-IN-1 (compound 1e) 是一种有效的 Enpp 和 carbonic anhydrase 抑制剂,对 NPP1、NPP2、NPP3、CA-II、CA-IX 的 IC50 值分别 1.36、1.35、3.00、0.88、1.02 μM。Enpp/Carbonic anhydrase-IN-1 对癌细胞具有抗增殖活性,对正常细胞具有低细胞毒性。Enpp/Carbonic anhydrase-IN-1 诱导细胞凋亡 (Apoptosis)。
- GC69131FrexalimabCAS: 2515463-86-0
Frexalimab (SAR441344; INX-021) 是一种靶向 CD40 配体 (CD40L) 的单克隆抗体。Frexalimab 具有用于多发性硬化症研究的潜力。
- GC69178Glychionide ACAS: 119152-50-0
Glychionide A 是一种黄酮苷,存在于 Glychirriza glabra 的根中。Glychionide A 促进 PANC-1 胰腺癌细胞的凋亡和自噬。Glychionide A 可用于癌症的研究。
- GC69380LirentelimabCAS: 2283348-97-8
Lirentelimab (AK002) 是一种人源化 IgG1 单克隆抗体,靶向唾液酸结合的 Ig 样凝集素 8 (SIGLEC8)。Lirentelimab 诱导 IL-5 激活的嗜酸性粒细胞细胞凋亡并抑制 IL-5 介导的肥大细胞激活。Lirentelimab 可用于嗜酸性胃炎、十二指肠炎的研究。
- GC69405L-Theanine-d5CAS: 1217451-85-8纯度: >99.00%
L-Theanine-d5 是 L-Theanine 的氘代物。L-Theanine (L-Glutamic Acid γ-ethyl amide)是一种存在绿茶叶片中的非蛋白氨基酸物质, 能阻断大脑中谷氨酸与谷氨酸受体结合,具有神经保护和抗氧化活性。 能通过口服 L-Theanine (L-Glutamic Acid γ-ethyl amide) 抑制皮层神经元兴奋从而产生抗应激作用 。
- GC69444MDM2-p53-IN-16CAS: 1917350-09-4纯度: >99.00%
MDM2-p53-IN-16 是一种 MDM2-p53 复合体抑制剂,解离人 MDM2-p532 复合体的 IC50 值为 4.3 nM。MDM2-p53-IN-16 可重激活 p53,诱导多形性成胶质细胞瘤 (GBM) 细胞凋亡和细胞周期阻滞。MDM2-p53-IN-16 可用于癌症研究。
- GC69590Nrf2 activator-2CAS: 2770448-53-6纯度: >98.00%
Nrf2 activator-2 (compound O15) 是一种蛇床子素衍生物,一种有效的 Nrf2 激动剂,在 293 T 细胞中的 EC50 为 2.9 μM。Nrf2 activator-2有效抑制 Keap1 和 Nrf2 的相互作用,从而显示出对 Nrf2 的激活作用。Nrf2 activator-2 显示细胞中泛素化 Nrf2 水平显着降低。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC68826 | Cantrixil | 2135511-22-5 | - | |
Cantrixil (TRX-E-002-1) 是 TRX-E-002 的活性对映异构体,是第二代超级苯并吡喃 (SBP) 化合物。Cantrixil 增加磷酸化 c-Jun 水平,导致卵巢癌细胞中半胱天冬酶介导的细胞凋亡。Cantrixil 对广泛的癌症表型具有有效的抗癌活性。 | ||||
| GC68857 | Cetrelimab | 2050478-92-5 | - | |
Cetrelimab (JNJ 63723283; JNJ 3283) 是一种靶向 PD-1 的人源化 IgG4κ 单克隆抗体。Cetrelimab 结合 PD-1 的 Kd 为 1.72 nM (HEK293 细胞)。由此,Cetrelimab 阻断 PD-1 与 PD-L1 和 PD-L2 的相互作用 (IC50 分别为 111.7 ng/mL 和 138.6 ng/mL)。Cetrelimab 还刺激外周 T 细胞,增加细胞因子 (IFN-γ, IL-2, TNF-α) 水平,并抑制体内肿瘤生长。 | ||||
| GC68873 | Citric acid trisodium | 68-04-2 | >98.00% | |
Citric acid trisodium 是一种天然防腐剂和食品酸味增强剂。Citric acid trisodium 诱导细胞凋亡 (apoptosis) 和细胞周期停滞在 G2/M 期和 S 期。Citric acid trisodium 通过降低抗氧化酶活性引起肝脏的氧化损伤。Citric acid trisodium 对小鼠造成肾毒性。 | ||||
| GC68882 | Cleomiscosin A | 76948-72-6 | - | |
Cleomiscosin A 是产于 Macaranga adenantha 的香豆素类木质素。Cleomiscosin A 对小鼠腹腔巨噬细胞分泌 TNF-alpha 具有活性。 | ||||
| GC68903 | cRIPGBM chloride | 2361988-77-2 | >99.00% | |
cRIPGBM chloride 是一种口服有效的促凋亡衍生物,cRIPGBM 可从多形性胶质母细胞瘤 (GBM) 癌症干细胞 (CSC) 中产生。cRIPGBM chloride 靶向受体相互作用蛋白激酶 2 (RIPK2) 以诱导半胱天冬酶 caspase 1 依赖性细胞凋亡。cRIPGBM chloride 抑制 RIPK2/TAK1 (促存活复合物) 的形成,并增加 RIPK2/caspase 1 (促凋亡复合物) 的形成。cRIPGBM chloride 在动物模型中发挥了强力的体内抗肿瘤活性。 | ||||
| GC68916 | CWI1-2 | 2408590-36-1 | >98.00% | |
CWI1-2是一种选择性抑制m6A识别蛋白IGF2BP2的抑制剂,能够破坏IGF2BP2与m6A修饰的目标转录本之间的相互作用。 | ||||
| GC68956 | Dehydrocorydaline (hydroxyl) | - | >99.00% | |
Dehydrocorydaline hydroxyl (13-Methylpalmatine) 是一种生物碱。Dehydrocorydaline hydroxyl 调节 Bax,Bcl-2 蛋白表达;激活 caspase-7,caspase-8,并使 PARP 失活。Dehydrocorydaline hydroxyl 能增强 p38 MAPK 活化,具有抗炎、抗癌等功效。Dehydrocorydaline hydroxyl 具有强大的抗疟疾作用,并具低细胞毒性 (细胞生存力> 90%), P. falciparum 3D7 strain (IC50=38 nM)。 | ||||
| GC69001 | Dostarlimab | 2022215-59-2 | >95.00% | |
Dostarlimab (TSR-042) 是一种人源化抗 PD-1 单克隆抗体。Dostarlimab 与人 PD-1 具有高亲和力,并竞争性地抑制其与其配体 PD-L1 和 PD-L2 的相互作用,IC50s 分别为 1.8 nM 和 1.5 nM。 | ||||
| GC69009 | (D)-PPA 1 TFA | - | >99.00% | |
(D)-PPA 1 TFA 是一种抗水解 D 肽拮抗剂。(D)-PPA 1 TFA 是一种有效的 PD-1/PD-L1 抑制剂。(D)-PPA 1 TFA 与 PD-1 结合的亲和力为 0.51 μM,体内外均有效。 | ||||
| GC69039 | Edratide | 433922-67-9 | >98.00% | |
Edratide (TV 4710) 是一种由 19 个氨基酸组成的合成肽,它基于人类抗 DNA 抗体的互补决定区 1 (CDR1),表达主要独特型 16/6 Id。Edratide 降低细胞凋亡 (apoptosis) (Apoptosis) 率并下调 caspase-8 和 caspase-3,上调 Bcl-xL。Edratide 具有研究系统性红斑狼疮 (SLE) 的潜力。 | ||||
| GC69062 | Enavatuzumab | 1062149-33-0 | >95.00% | |
Enavatuzumab (PDL192; ABT-361) 是一种人源化 IgG1 单克隆抗体,靶向 TNF 样细胞凋亡弱诱导剂受体 (TWEAK)。TWEAK (Fn14; TNFRSF12A) 是 TWEAK 受体 (TweakR) 的天然配体,可刺激多种细胞反应。Enavatuzumab 通过直接的 TweakR 信号和抗体依赖性细胞介导的细胞毒性 (ADCC) 诱导肿瘤生长抑制。Enavatuzumab 可以主动募集和激活骨髓效应细胞来杀死肿瘤细胞。Enavatuzumab 在体外和体内抑制各种人类 TweakR 阳性癌细胞系和异种移植物的生长。 | ||||
| GC69070 | Enpp/Carbonic anhydrase-IN-1 | 2883495-35-8 | >99.00% | |
Enpp/Carbonic anhydrase-IN-1 (compound 1e) 是一种有效的 Enpp 和 carbonic anhydrase 抑制剂,对 NPP1、NPP2、NPP3、CA-II、CA-IX 的 IC50 值分别 1.36、1.35、3.00、0.88、1.02 μM。Enpp/Carbonic anhydrase-IN-1 对癌细胞具有抗增殖活性,对正常细胞具有低细胞毒性。Enpp/Carbonic anhydrase-IN-1 诱导细胞凋亡 (Apoptosis)。 | ||||
| GC69105 | FG-3019 | 946415-13-0 | >95.00% | |
FG-3019 (Pamrevlumab) 是一种重组人源化抗体,可与结缔组织生长因子 (CTGF) 结合。FG-3019 可用于特发性肺纤维化 (IPF) 的研究。 | ||||
| GC69131 | Frexalimab | 2515463-86-0 | - | |
Frexalimab (SAR441344; INX-021) 是一种靶向 CD40 配体 (CD40L) 的单克隆抗体。Frexalimab 具有用于多发性硬化症研究的潜力。 | ||||
| GC69163 | GL0388 | 2886772-68-3 | >98.00% | |
GL0388 是一种 Bax 激活剂,可导致 Bax 插入线粒体膜。GL0388 对多种癌细胞具有抗增殖活性,IC50 值为 0.299-1.57 μM。GL0388 激活 Bax 并诱导 Bax 介导的细胞凋亡。GL0388 在体内抑制乳腺癌异种移植肿瘤的生长。 | ||||
| GC69178 | Glychionide A | 119152-50-0 | - | |
Glychionide A 是一种黄酮苷,存在于 Glychirriza glabra 的根中。Glychionide A 促进 PANC-1 胰腺癌细胞的凋亡和自噬。Glychionide A 可用于癌症的研究。 | ||||
| GC69304 | IW927 | 389142-48-7 | >99.00% | |
IW927 是一种有效的小分子拮抗剂,可以阻断 TNF-α 与 TNFRc1 的结合,其 IC50 值为 50 nM, 并且可以破坏 TNFα 诱导的 IκB 磷酸化,其 IC50 值为 600 nM。 | ||||
| GC69316 | JNJ-1013 | 2597343-08-1 | >99.00% | |
JNJ-1013 是一种有效的选择性 IRAK1 降解剂,对 IRAK1、IRAK4、VHL FP 的 IC50 值分别为 72、443、1071 nM。JNJ-1013 诱导细胞凋亡 (Apoptosis) 并增加 cleavaged PARP 的表达。JNJ-1013 降低 IRAK1、p-IKBα、pSTAT3(Tyr705) 的表达。 | ||||
| GC69364 | LDCA | 349106-80-5 | >99.00% | |
LDCA 是一种双重打击代谢调节剂,可抑制 LDH-A 酶活性,刺激恶性群体的凋亡。LDCA 可用于致癌进展的研究。 | ||||
| GC69379 | Lipid 8 | 2226547-25-5 | >98.00% | |
Lipid 8 是一种可电离的氨基脂质,可用于合成脂质纳米颗粒。 | ||||
| GC69380 | Lirentelimab | 2283348-97-8 | - | |
Lirentelimab (AK002) 是一种人源化 IgG1 单克隆抗体,靶向唾液酸结合的 Ig 样凝集素 8 (SIGLEC8)。Lirentelimab 诱导 IL-5 激活的嗜酸性粒细胞细胞凋亡并抑制 IL-5 介导的肥大细胞激活。Lirentelimab 可用于嗜酸性胃炎、十二指肠炎的研究。 | ||||
| GC69405 | L-Theanine-d5 | 1217451-85-8 | >99.00% | |
L-Theanine-d5 是 L-Theanine 的氘代物。L-Theanine (L-Glutamic Acid γ-ethyl amide)是一种存在绿茶叶片中的非蛋白氨基酸物质, 能阻断大脑中谷氨酸与谷氨酸受体结合,具有神经保护和抗氧化活性。 能通过口服 L-Theanine (L-Glutamic Acid γ-ethyl amide) 抑制皮层神经元兴奋从而产生抗应激作用 。 | ||||
| GC69444 | MDM2-p53-IN-16 | 1917350-09-4 | >99.00% | |
MDM2-p53-IN-16 是一种 MDM2-p53 复合体抑制剂,解离人 MDM2-p532 复合体的 IC50 值为 4.3 nM。MDM2-p53-IN-16 可重激活 p53,诱导多形性成胶质细胞瘤 (GBM) 细胞凋亡和细胞周期阻滞。MDM2-p53-IN-16 可用于癌症研究。 | ||||
| GC69590 | Nrf2 activator-2 | 2770448-53-6 | >98.00% | |
Nrf2 activator-2 (compound O15) 是一种蛇床子素衍生物,一种有效的 Nrf2 激动剂,在 293 T 细胞中的 EC50 为 2.9 μM。Nrf2 activator-2有效抑制 Keap1 和 Nrf2 的相互作用,从而显示出对 Nrf2 的激活作用。Nrf2 activator-2 显示细胞中泛素化 Nrf2 水平显着降低。 | ||||
